Heart failure is a global health challenge that demands innovative therapeutic approaches. Evotec’s pioneering iPSC-derived cardiomyocytes offer a promising solution, addressing the critical challenges of immune rejection, graft-induced arrhythmia, and scalable production.  

The growing global burden of heart failure

Heart failure (HF) remains a leading cause of mortality, affecting millions worldwide​¹​. Current estimations predict that there will be over 8 million people in the United States alone living with HF by 2030^​2​. The condition is exacerbated by the heart’s limited regenerative capacity, as cardiomyocytes — the cells responsible for heart muscle contraction — have minimal ability to regenerate after injury. Consequently, a single myocardial infarction can result in the irreversible loss of billions of cardiomyocytes, leading to heart failure with reduced ejection fraction (HFrEF)​³​. 

Traditional treatments focus on managing symptoms and slowing the progression of HF but fail to address the root cause — the loss of functional cardiac tissue. Over time, patients will reach the end stage of HF, experiencing a vastly diminished quality of life, with ventricular assist devices or rare heart transplantation being final treatment options. As the global population ages and cardiovascular risk factors rise, there is an urgent need for novel therapies that go beyond symptom management, to regenerate lost heart tissue and prevent HF from progressing. 

One promising avenue is regenerative cell therapy using induced pluripotent stem cells (iPSCs). In this article, we explore the current challenges in developing cell therapies for heart failure and Evotec’s innovative approach to overcoming them, with recent findings from their iPSC-derived cardiomyocyte (iCM) Heart Repair program. 

The promise of regenerative cell therapy for HF

Regenerative medicine, especially iPSC-based therapies, holds tremendous potential in addressing the unmet needs of HF patients. iPSCs can be reprogrammed from adult cells, and with unlimited proliferative capacity, they have the unique ability to differentiate into any cell type. 

Thus, iPSCs offer a renewable source of cardiomyocytes. This makes iPSC cell-derived cardiomyocytes (iCM) an ideal candidate for providing novel and curative HF therapies, with the potential to replenish lost heart cells in HF patients and restore cardiac function. However, the path to clinical application is fraught with challenges. 

Challenges in cardiac cell therapy

One of the primary challenges with allogeneic iPSC-based therapies is the prevention of immune rejection. Allogeneic iCM are recognized as foreign by the patient’s immune system. This leads to rejection unless immunosuppressive drugs are used​4​. However, long-term immunosuppression carries significant risks and is not a viable solution for all patients.  

Moreover, there’s the challenge of preventing graft-induced arrhythmias. These can occur when transplanted cardiomyocytes do not integrate properly with the host tissue, leading to irregular heartbeats.  

Another key challenge is successfully scaling up production to meet clinical needs. HF patients require over a billion iCM for effective treatment. However, producing large doses of iCM demands cost-effective, scalable processes. Additionally, ensuring consistent quality and purity of these cells at increased scale is critical for their therapeutic success. 

Evotec’s iCM Heart Repair program, in collaboration with the Medical Center Hamburg-Eppendorf “UKE”, has been developed to address these challenges. This collaborative program focuses on the development of first-class non-immunogenic iCM that can be produced at scale, offering a promising off-the-shelf treatment that can meet the global demand for HF therapies.  

Immune-shielded iCM are protected from T cells and NK cells

As part of Evotec’s iCM Heart Repair program, researchers at Evotec evaluated iCM immune-shielding strategies for tissue replacement in HF patients. In this study, the researchers first developed a robust production process of wildtype (wt) iCM cells, using the fully characterized GMP iPSC line in small-scale GMP-compliant bioreactors. Yield evaluation with flow cytometry demonstrated an exceptionally high purity of >97% cardiomyocyte marker, cardiac troponin T (cTNT).

 To investigate strategies to prevent allogeneic immune rejection, two genetically engineered iCM lines were chosen, human leukocyte antigen (HLA)- encoded class I and II knockout iCM, and iACT iCM​^5​​,6​ (panCELLa Induced Allogenic Cell Tolerance Stealth Cells™). These lines contain genetic modifications to inactivate human leukocyte antigen factors I and II (HLA-I/II KO), or overexpress immune-shielding factors (iACT), which were engineered to the iPSC prior to their differentiation. Thus, both iCM are designed to prevent immune cell activation and cytokine release.  

Using in vitro assays, the two iCM lines were co-cultured with primed T cells or expanded natural killer (NK) cells. The subsequent release of the cytokine IFNγ and killing of the iCM was measured to investigate the immune-suppressing potential of HLA-I/II KO and iACT immune-shielded iCM. 

Figure 1: Wild type iCM (wt), HLA-I/II KO, and iACT immune-shielded iCM were co-cultured with primed T cells or expanded NK cells of human donors. iCM survival and IFNγ release from immune cells was measured after 6-24 hours.

Results of the in vitro co-culture assays (Figure 1) showed iACT iCM provide efficient protection against NK cells, but only moderate protection against T cells. Contrastingly, HLA-I/II KO iCM were shown to be vulnerable to NK cells due to the “missing-self-response”, but highly efficient against T cells. 

Engineering an improved iCM cell line  

To improve the therapeutic potential of immune-shielded iCM, Evotec has developed its proprietary EvoCloaking iPSC line. The novel cell line is based on HLA-I/II KO, with an additional innovative anti-NK cell strategy to increase its immune-shielding properties. 

In vitro data supports that EvoCloaking iPSC-derived iCM can reduce cytokine release and are protected against both T cells and NK cells. This means the proprietary cell line offers an innovative strategy to ensure the acceptance and persistence of engrafted iCM, improving the safety and long-term function of the therapy, while avoiding the need for immunosuppressants. 

In addition to its immune-shielding properties, EvoCloaking iPSC-derived iCM are genetically engineered to safeguard against tumorgenicity, with a drug inducible kill-switch allowing for the elimination of undesired proliferating cells. Importantly, the proprietary cell line will also contain a genetic modification to avoid graft-induced arrhythmia in derived iCM. This is supported by in vitro data, and is currently tested on arrhythmia-prone pigs.

EvoCloaking iCM are highly pure cells optimized for off-the-shelf product use as a single cell suspension. In heart injury guinea pig models, efficient iCM engraftment has been demonstrated when injected as single cell suspensions. Consequently, catheter-based interventional administration should be compatible with this product format.

Evotec's scalable therapeutics platform

The iCM Heart Repair Program aims to overcome challenges associated with large-scale iCM production. Using Evotec’s GMP-compatible manufacturing infrastructure, scalable and cost-effective bioreactor processes have been established for iPSC expansion and differentiation in 3D. Furthermore, predictive in-process controls and advanced in silico modeling have been implemented into the differentiation process, to optimize cell yield and purity. 

Evotec’s cell therapy pipeline expansion to include immune-shielded iCM is testament to its commitment to allogeneic cell therapeutics. Our unique end-to-end platform and expertise support the development and manufacturing of off-the-shelf iPSC therapies for a range of diseases and conditions, from cancer and autoimmune disease to diabetes and cardiovascular disease. The integrated platform covers development stages from early exploration to GMP compliant scale-up for further research, pre-clinical, and clinical studies. 

Figure 2: An overview of Evotec’s end-to-end platform for iPSC-based therapeutics

The future of heart repair

The development of immune-shielded iPSC-derived cardiomyocytes represents a significant advancement in the field of regenerative medicine. This therapy could revolutionize the treatment of heart failure, offering a solution that addresses the underlying cause of the disease, rather than just managing symptoms. Integrated iCM development and manufacturing processes are also ensuring the scalable, cost-effective production of this therapy, holding great potential for meeting the increasing global demand for curative HF treatment.

Evotec’s commitment to innovation and excellence in the field of regenerative medicine positions it as a leader in the development of next-generation therapies. By addressing the key challenges in iCM therapy, including scalable production, immune rejection, and graft-induced arrhythmias, Evotec is paving the way for a new era in heart failure treatment.

Moreover, the broader impact of this research by Evotec extends beyond heart failure, as the principles of immune-shielding and scalable bioprocessing can be applied to other cell therapies, opening new avenues for treating a range of diseases.

Discover more about Evotec’s innovative iPSC-based therapies

Download the iCM research poster

References

(1)    Savarese, G.; Becher, P. M.; Lund, L. H.; Seferovic, P.; Rosano, G. M. C.; Coats, A. J. S. Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology. Cardiovasc Res 2023, 118 (17), 3272–3287. https://doi.org/10.1093/CVR/CVAC013.
(2)    Golla, M. S. G.; Hajouli, S.; Ludhwani, D. Heart Failure and Ejection Fraction. StatPearls 2024.
(3)    Laflamme, M. A.; Murry, C. E. Regenerating the Heart. Nature Biotechnology 2005 23:7 2005, 23 (7), 845–856. https://doi.org/10.1038/nbt1117.
(4)    Lanza, R.; Russell, D. W.; Nagy, A. Engineering Universal Cells That Evade Immune Detection. Nature Reviews Immunology 2019 19:12 2019, 19 (12), 723–733. https://doi.org/10.1038/s41577-019-0200-1.
(5)    Harding, J.; Vintersten-Nagy, K.; Yang, H.; Tang, J. K.; Shutova, M.; Jong, E. D.; Lee, J. H.; Massumi, M.; Oussenko, T.; Izadifar, Z.; Zhang, P.; Rogers, I. M.; Wheeler, M. B.; Lye, S. J.; Sung, H. K.; Li, C. J.; Izadifar, M.; Nagy, A. Immune-Privileged Tissues Formed from Immunologically Cloaked Mouse Embryonic Stem Cells Survive Long Term in Allogeneic Hosts. Nature Biomedical Engineering 2023 8:4 2023, 8 (4), 427–442. https://doi.org/10.1038/s41551-023-01133-y.
(6)    Harding, J.; Vintersten-Nagy, K.; Shutova, M.; Yang, H.; Tang, J. K.; Massumi, M.; Izaidfar, M.; Izadifar, Z.; Zhang, P.; Li, C.; Nagy, A. Induction of Long-Term Allogeneic Cell Acceptance and Formation of Immune Privileged Tissue in Immunocompetent Hosts. bioRxiv 2019, 716571. https://doi.org/10.1101/716571.

Transitioning to continuous manufacturing for commercial biologics production

Transitioning to continuous manufacturing for commercial-scale biologics production represents a significant – but highly beneficial – shift in biomanufacturing strategies. This approach not only promises reduced costs, enhanced efficiency, and productivity, but also ensures consistent product quality ¹.

As part of this three-part blog series, we’ve previously covered the current issues faced in biologics production, and how continuous manufacturing helps to address these. In this final blog of our series, we delve into the steps required to transition from traditional fed-batch processes to continuous manufacturing, focusing on feasibility, commercial process development, and process validation.

Assessing feasibility

The first step in transitioning to continuous manufacturing is a thorough 3-month feasibility assessment. This involves evaluating the existing fed-batch process and identifying potential challenges and opportunities for continuous operation. Just – Evotec Biologics leverages its extensive expertise in continuous manufacturing to conduct detailed feasibility studies, which include:

• Cell line assessments: We run ‘mock perfusion’ cultures in scale-down models with existing or new cell lines and assess growth, productivity, and product quality.
  
  
• Verification at 3L bioreactor scale: The most promising cultures from the cell line assessments are re-run at the 3L scale and the perfusate used to screen downstream platform conditions using high-throughput technologies.
  
  
• COGM modeling comparison: Our experts compare data from the fed-batch performance with those generated during the feasibility study. This allows for an evaluation of the COGM benefits of switching to our continuous manufacturing platform.

Intrigued about how our feasibility studies are conducted? Uncover further details here

Figure 1: Timeline of a minimally resourced, 3-month feasibility study, demonstrating margin gains, reduce risk, and validate ROI assumptions

The COGM models used in our feasibility studies are based on Net Present Costs (NPC). NPC calculations estimate cash flows by calculating operational costs and discounting over time using a cost of capital parameter ². We use these models to compare the COGM for continuous manufacturing with existing fed-batch processes, across different post-launch demand situations. Continuous manufacturing in J.POD^® facilities typically show lower operational costs, irrespective of production rates, due to our flexible facility design ². 

Check out our previous blog to learn how continuous manufacturing can lower biologics production costs by 75 %  

Commercial process development

Once feasibility is established, the next step is to develop a robust, scaled-up commercial process. This involves:

1. Establishing a full 25-day end-to-end continuous manufacturing process: Establishing a continuous manufacturing process and evaluating robustness over a 25-day process, to ensure the biologic’s product quality attributes (PQAs) are maintained for the duration of the run.
   
   
2. A 1000-L engineering run: At our innovative cGMP facility , a commercial-scale run is conducted to demonstrate process efficacy
   
   
3. Clinical manufacturing runs: Supply subsequent clinical trials. Material is taken from these runs to generate and qualify the reference standard and perform stability studies on the drug substance (DS), ensuring regulatory compliance and future commercial success

During this development stage, we ensure the process is robust and can be seamlessly scaled up to meet commercial production demands. Our J.POD^®  facilities are designed to be highly adaptable, and enable a flexible process that can quickly adjust to changing market demands. Working together with our partners, we refine the continuous manufacturing process to maximize yield, productivity, and product quality.

Process validation

The final step in the transition is process validation. We perform process characterization, process validation and other Biologics License Application (BLA)-enabling studies. These include facility risk assessments, DS freeze/thaw studies, as well as shipping validation assessments.

These studies are critical for regulatory compliance and ensure consistent product quality ³. Ensuring the process meets all regulatory requirements, Just – Evotec Biologics has extensive experience in navigating regulatory landscapes, facilitating a smoother approval process.

Step into the new era of biologics manufacturing

Transitioning to continuous manufacturing is a transformative step for commercial biologics production. It offers significant benefits, including cost reduction, enhanced efficiency, and improved product quality. The additional advantage of our short feasibility studies is that they allow for the potential benefits of transitioning to be evaluated prior to committing to a full transition, substantially reducing risks. By leveraging advanced technologies and expert guidance from Just – Evotec Biologics, biopharma companies can successfully navigate this transition, stepping into the new era in biologics manufacturing.

Proven expertise in commercial manufacturing

At Just – Evotec Biologics, we wield our expertise to focus on developing and manufacturing antibody and antibody-related products, as well as biologic formats expressed in Chinese Hamster Ovary (CHO) cells. The company has demonstrated its cGMP manufacturing success over the past ten years. We provide support filing BLAs and Investigational New Drug (IND) applications. Having surpassed several cGMP compliance milestones, across the US, Canada, and the UK, Just – Evotec Biologics is positioned as a trusted global partner in the journey towards making life-saving therapies accessible worldwide.

Find out how Just – Evotec Biologics can elevate your biomanufacturing processes

References

1. From Development to Delivery: How Continuous Manufacturing is Redefining the Commercial Landscape for Biologics - Science Pool. Available at: https://sciencepool.evotec.com/from-development-to-delivery-how-continuous-manufacturing-is-redefining-the-commercial-landscape-for-biologics/ Accessed 11 August, 2024
2. Garcia, F.A. and Gefroh, E. Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD^® facility. Drug Discovery Today. (2023); 28(7):103619. https://doi.org/10.1016/j.drudis.2023.103619 
3. Modality Solutions, Battista R. Unlocking FDA Insights: Open Data Files for Successful BLA Submissions. Available at: https://www.modality-solutions.com/unlocking-fda-insights-open-data-files-successful-bla-submissions/ Accessed 11 August, 2024

Note: This article was developed for Bio Europe Supplement, EBR Autumn Edition 2024, Samedan Ltd 

Just – Evotec Biologics explores how, through offering enhanced productivity, cost efficiency, agility and more, continuous manufacturing processes and facilities are improving global access to biologics. 

Learn More

Just - Evotec Biologics is at the forefront of biomanufacturing innovation with its JP3 platform. By integrating intensified perfusion cell culture and fully connected downstream processing, we achieve remarkable productivity and cost efficiency. Our approach not only boosts output but also ensures consistent, high-quality biotherapeutics.

Leveraging AI/ML technologies and advanced process intensification, Just - Evotec Biologics is setting new industry standards. Our continuous manufacturing process significantly reduces costs and expands global access to essential biotherapeutics.

Download

Machine Learning (ML) is becoming critical for the design and development of therapeutics. Just-Evotec Biologics has created a Humanoid Antibody Library for the discovery of biopharmaceuticals that is the first step towards leveraging artificial intelligence and ML. 

In this publication we describe how we have started the validation of the library by isolating antibodies against a target of pandemic concern, SARS-CoV-2.

We successfully identified a panel of human monoclonal antibodies that are novel, diverse, and pharmacologically active. These first-generation antibodies exhibited neutralization of SARS-CoV-2 viral infectivity across multiple strains and indicated high developability potential.

These results demonstrate the applicability of our platform for effective therapeutic antibody discovery.

Learn More

In the complex world of biopharmaceutical development, Chemistry, Manufacturing, and Controls (CMC) activities are critical yet often fraught with challenges. Just-Evotec Biologics offers a suite of innovative solutions designed to mitigate these risks, with their J.MD™ Molecular Design service standing out as a key player in this arena.

The Role of J.MD™ Molecular Design

The J.MD™ Molecular Design service is part of Just-Evotec Biologics’ comprehensive J.DESIGN™ platform, which integrates advanced computational tools and high-throughput methodologies to streamline the development process. This service focuses on selecting an optimal lead and optimizing the molecular design of biologics to ensure manufacturability, stability, and efficacy from the earliest stages of development.

Evaluating Early Team Supply Material

One of the primary ways J.MD™ helps derisk CMC efforts is by evaluating early team supply material produced in stable pools. This early biophysical characterization is crucial for identifying potential issues that could arise later in the development process. By addressing these issues upfront, Just-Evotec Biologics helps partners avoid costly and time-consuming setbacks.

Derisking the CMC Journey

The CMC journey involves numerous stages, from initial development to production-scale manufacturing. Each stage presents unique challenges that can impact the overall success of a biopharmaceutical product. Just-Evotec Biologics’ J.MD™ service helps derisk this journey in several ways:

• Predictive Computational Tools: The Abacus™ tool within the J.MD™ toolbox uses predictive algorithms to assess the manufacturability and stability of different molecular variants. This allows for the selection of lead candidates with optimal properties, reducing the risk of failure in later stages¹.

• High-Throughput Screening: By leveraging high-throughput screening methods, J.MD™ can rapidly evaluate multiple variants, accelerating the development timeline and ensuring that only the most promising candidates move forward².

• Integrated Development Approach: The J.MD™ service is part of a larger, integrated approach that includes cell line development, process optimization, and continuous manufacturing. This holistic approach ensures that all aspects of the CMC process are aligned and optimized for success³.

• Regulatory Support: Just-Evotec Biologics also provides comprehensive regulatory support, helping partners navigate the complex landscape of biopharmaceutical regulations. This support is crucial for ensuring that products meet all necessary standards and can be brought to market efficiently⁴.

Conclusion

In summary, Just-Evotec Biologics’ J.MD™ Molecular Design service plays a pivotal role in derisking CMC efforts for biopharmaceutical partners⁵. By evaluating early team supply material, leveraging predictive computational tools, and integrating a comprehensive development approach, J.MD™ helps ensure that the CMC journey is as smooth and successful as possible. This not only saves time and resources but also increases the likelihood of bringing effective and safe biopharmaceutical products to market.

Learn More

References

1. Just-Evotec Biologics’ Abacus™ tool 
2. High-throughput screening methods
3. Integrated development approach
4. Regulatory support
5. Derisking CMC efforts for biopharmaceutical partners

In the evolving landscape of cancer treatment, Immuno-Oncology (IO) has been at the forefront for the past 15 years, revolutionizing our approach to battling this formidable disease. Immunotherapy, which harnesses the body's immune system to fight cancer, offers hope where traditional therapies have often fallen short. For instance, in advanced stage IV melanoma, the median survival has improved from 6 months to 6 years over the past decade thanks to immunotherapy.

However, the journey from discovery to clinical application is fraught with challenges. Why do some patients respond to immunotherapy while others do not? What opportunities exist for developing the right combination therapies? How can we better select the right cancer indications for a particular IO target? How can we ensure the success of these treatments across diverse patient populations?

At Evotec, our immunologists are equipped with the expertise and experience to support your IO projects from target identification through to clinical trials. Whether you require a comprehensive and strategic partnership or targeted support at critical stages, our capabilities can synergize with your efforts to make a tangible difference.

Comprehensive Support Across the Immuno-Oncology Spectrum

In-depth Immunology Expertise

Our team’s knowledge spans from innate to adaptive immunity, providing a robust foundation for developing cutting-edge cancer immunotherapies. We offer:

●    Genetic Engineering of Primary Immune Cells: Optimizing target validation for effective therapy development.
●    Bespoke In Vitro Immunological Assays: Custom-designed assays to evaluate immune responses and the potency of immunotherapeutic candidates.
●    Single-Cell Level Immunotherapy Assessment: Utilizing Immunological Synapse technology for precise drug discovery.

Preclinical Animal Models Dedicated to IO

Moving forward with candidates within the drug discovery journey requires robust and tailored in vivo models for IO:
●    Syngeneic Mouse Models: Developed with various tumor-immune phenotypes and responsiveness to checkpoint inhibitors; these models help in assessing therapeutic efficacy, modulation of the immune response (tumor microenvironment and periphery), as well as pharmacodynamics features (PK/PD).
●    Humanized Mouse Models: Presenting a functional human immune system with the possibility of xenografting a human tumor. These models are pivotal for particular therapeutic modalities such as biologic therapeutics (e.g., immune cell engagers) or cell therapies; they could also be interesting for early toxicology studies looking at immune-related adverse events.

Translational Validation Using Relevant Patient Samples

To bridge the gap between in vitro models done with primary human immune cells isolated from healthy donors and in vivo models in the drug discovery process:
●    Broad Clinical Network: Collaborations with hospitals and clinicians to select the relevant samples for the project.
●    Translational Validation of Therapies: Access to cancer patient samples ensures that therapies are effective in a patient context.
●    Enhanced Target Validation: Possibility to develop on-target biomarker assays or validate target expression in a particular indication.

Advanced Technological Integration

Our approach integrates cutting-edge technologies to de-risk your drug development strategy:
●    High-Throughput Imaging and Analysis: Tools like the ImageStream X and Operetta provide high-speed, high-resolution insights into immune cell interactions.
●    Complex Flow-Cytometry and Functional Assays: These analyses on fresh human tumor samples facilitate target engagement validation and biomarker identification.
●    Omics Technologies: Including scRNAseq, TCR sequencing, and proteomics, to uncover novel biomarkers and therapeutic targets.

Precision Medicine and Biomarker Strategies

By incorporating biomarker strategies early in the discovery process, we enhance the understanding of disease mechanisms and improve patient stratification for clinical trials. Our efforts in precision medicine are aimed at identifying the right therapeutic interventions for the right patients, thereby increasing the likelihood of clinical success.

The Evotec Advantage

Evotec’s experienced IO team supports your projects from the lab bench to the patient bedside. Our comprehensive services include:
●    Functional In Vitro Immunological Assays: Supporting programs for small molecules, biologics, and cell therapies.
●    In Vivo Rodent Models: Essential for preclinical testing of therapeutic efficacy and safety.
●    Translational Research and Patient Sample Access: Enhancing the relevance and translatability of preclinical findings.

Driving Success in Immuno-Oncology

Our integrated approach, combining deep immunological expertise with advanced technologies and translational capabilities, ensures that we address the complex challenges of IO drug discovery. By partnering with Evotec, you gain access to a wealth of knowledge and resources designed to propel your project forward, from the initial stages of discovery to the clinical validation of novel therapies.
For more information on how Evotec can support your Immuno-Oncology projects, visit our website or contact us at info@evotec.com.

Conclusion

The revolution in cancer immunotherapy is just beginning, and the journey to effective treatments requires collaboration, innovation, and expertise. At Evotec, we are committed to advancing the field of Immuno-Oncology, providing the tools and support necessary to transform groundbreaking discoveries into life-saving therapies. Join us in this mission and let’s make a difference in the fight against cancer.
Contact us today to speak with one of our immunologists and explore how we can progress your IO projects together.

Learn More

In the dynamic world of biopharmaceuticals, cost efficiency is a critical factor, especially for start-up companies navigating the complex landscape of drug development. Continuous biomanufacturing is an innovative approach that has garnered significant attention for its potential to significantly reduce the cost of commercial biologics. Less often discussed, however, is the potential for continuous biomanufacturing platforms for first-in-human (FIH) clinical trials. This method not only streamlines the production process but also offers substantial savings during the manufacture of material intended for early phase antibody development, making it an attractive option for emerging biotech firms.

What is Continuous Biomanufacturing?

Continuous biomanufacturing is a process where the production of biopharmaceuticals occurs in a seamless, ongoing manner, as opposed to traditional batch manufacturing, which involves discrete, separate production cycles. This continuous approach leverages advanced technologies and automation to maintain a steady flow of production, ensuring consistent quality and efficiency.

Cost Efficiency in Early-Stage Clinical Trials

One of the most compelling advantages of continuous biomanufacturing is its ability to produce large quantities of biopharmaceuticals in a single run. This is particularly beneficial for early phase clinical trials, where the initial supply can often be enough to cover subsequent Phase 2a and Phase 2b clinical studies. Here’s why emerging biopharmaceutical companies benefit:

1. Elimination of Additional Batches: Traditional batch manufacturing often requires multiple production runs to meet the demands of Phase I and II clinical trials. Each additional batch incurs significant costs, including raw materials, labor, and quality control. Continuous biomanufacturing, however, can produce a large enough supply in one go, eliminating the need for these extra batches.
   
   
2. Consistent Quality: Continuous processes are designed to maintain a high level of consistency and offer more levers to tightly control critical quality attributes than fed-batch processes. Supplying multiple clinical trials from the same lot of material ensures a perfect level of consistency which is crucial for regulatory approval and patient safety, further streamlining the development process.
   
   
3. Time Savings: By producing all necessary material in one continuous run, companies can significantly reduce the overall time required to manufacture the material they need for clinical trials. They avoid the challenge of finding available slots in their CDMO’s production schedule. This accelerates the overall timeline for clinical trials, allowing for faster progression through the development pipeline.

Financial Impact for Start-Ups

For start-up companies, the financial implications of continuous biomanufacturing are profound. The cost savings from eliminating additional batches can amount to millions of dollars. These funds can then be redirected towards other critical areas of drug development, such as:

1. Research and Development: Investing in expanding the pipeline of new candidate biopharmaceuticals. 
   
   
2. Clinical Trials: Initiating additional clinical studies for other disease indications. 
   
   
3. Extending the funding runway: Providing the company with the longest possible time before it needs to raise additional funding. 
   
   

Learn More

Biopharmaceutical companies increasingly want to convert fed-batch manufacturing processes to continuous platforms. We teamed up with GLOBAL Regulatory Writing & Consulting for this whitepaper so that you can learn:

• How to meet regulatory expectations when switching to continuous manufacturing
• The importance of appropriate risk assessments
• How to demonstrate comparability with previously manufactured material

Learn More

From Batches to Brilliance: The Benefits of Continuous for Commercial Manufacturing

As we covered in the first blog of this series,  biotherapeutics sponsor companies face numerous challenges in process development and manufacturing. This largely comes down to the overwhelming reliance on fed-batch processes in the biologics industry, which bring lengthy production timelines, process risks, and supply chain vulnerabilities. These issues contribute to the high cost structure of biologics and limit the accessibility of these vital therapies worldwide.

Continuous manufacturing is a rapidly emerging alternative production process to fed-batch processing. Biological products are produced in an uninterrupted flow, resulting in a steady and consistent output of product. This approach addresses many of the challenges with fed-batch systems, including: 

• Reduced process costs and lower cost of goods manufactured (COGM)
• Scalability and adaptability to fluctuating demands
• Fewer process and scalability risks

Read on as we explore these benefits of continuous manufacturing for commercial manufacturing, describing how they can address the high cost structure associated with biologics, and help to meet the rising global demand for these life-saving therapies. 

Cost reduction

Continuous manufacturing can reduce the COGM by up to 75% compared to traditional fed-batch processes (1), while also achieving 10-fold higher productivity (Figure 1). 

Figure 1: Productivity of a fed-batch process compared with a continuous approach. 

This is partly achieved through workflow automation, which minimizes labor costs while improving production efficiency (Figure 2). Additionally, compared with fed-batch units that require large facilities to store product intermediates, continuous operations are highly intensified and have a much smaller facility footprint, further reducing operational costs. Continuous operations also enable manufacturers to optimize resource use and reduce waste, leading to additional cost savings. 

Figure 2: Unit operations and labor resources needed to run a continuous process compared to traditional fed-batch process

Scalability and adaptability

A continuous approach allows for a much more agile process, driven by greater scalability and adaptability. For instance, J.POD^® biomanufacturing facilities from Just – Evotec Biologics support throughput from less than 10 kg to over 2,000 kg per year of protein-based biologics including mAbs and biosimilars. Production can be rapidly scaled up by increasing bioreactor numbers and extending run times with intensified continuous manufacturing technology. This enables manufacturers to adjust production levels quickly in response to market demand. 

Figure 3: How Just – Evotec Biologics’ platform steady-state intensified continuous manufacturing process can be scaled

Reduced risk

Continuous manufacturing reduces risks by ensuring consistent product quality. A DoE approach can be used to fine tune product quality attributes (PQAs) during development and advanced monitoring in production can maintain process consistency. This consistency is crucial for reducing regulatory risks and ensuring the efficacy and safety of biologics. 

This innovative manufacturing approach also enhances supply chain and financial security. With a smaller facility footprint and reduced operational costs, the financial risk for sponsor companies is substantially reduced. The modular design of facilities like J.POD allows for rapid deployment and scaling, mitigating geopolitical disruptions and financial risks associated with traditional fed-batch processes.

Making the transition is easier than you think. Explore the benefits and the process in more detail in our whitepaper

Unravelling the blueprint for success 

Transitioning to continuous manufacturing for commercial supply, in modular facilities like J.POD, offers a robust, cost-effective, and adaptable solution to address the unmet demand for biologics globally. Yet despite the clear benefits of continuous manufacturing, many manufacturers have yet to make the transition from fed-batch systems. This is often due to a lack of understanding of regulatory uncertainties, deployment pathways, and process development activities. 

Just – Evotec Biologics leverages over a decade of expertise in continuous manufacturing to help clients convert their fed-batch processes to its continuous manufacturing platform ready for commercial production. Commercial supply runs with its continuous manufacturing platform can be performed within one of its J.POD biomanufacturing facilities. These modular, scalable facilities are designed to offer the following benefits: 

• Maximized yields and cost efficiency – J.POD facilities utilize intensified continuous perfusion culture supporting high cell densities and product yield. The facilities also minimize operational costs through workflow automation, intensified bioprocessing, optimized resource use, and more.

• Rapid deployment and advanced agility – J.POD facilities are built using modular cleanroom pods that can be swiftly deployed and assembled. This design allows for flexible and scalable manufacturing capacity, enabling the facility to adapt quickly to changing production needs.

• Risk resilience – With established facilities in the US and Europe, J.POD mitigates the risk of geopolitical or supply disruptions. These facilities are standardized in design and operation, allowing for seamless process transfer between sites. 

Discover the full benefits of J.POD facilities 

References

1. Garcia, F.A. and Gefroh, E. Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD® facility. Drug Discovery Today. (2023); 28 (7): 103619. https://doi.org/10.1016/j.drudis.2023.103619